trending Market Intelligence /marketintelligence/en/news-insights/trending/UWUMlfOJ6-jUnkdDZiiEXg2 content esgSubNav
In This List

FibroGen's anemia drug meets primary endpoints in phase 3 trials

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


FibroGen's anemia drug meets primary endpoints in phase 3 trials

FibroGen Inc.'s Roxadustat met the primary endpoints in two phase 3 anemia studies in China.

The drug was being evaluated in dialysis-dependent and non-dialysis dependent patients with chronic kidney disease. Both patient types experienced an increase in their hemoglobin levels and achieved the desired effect under the studies.

The data will support a new drug application in China. FibroGen is co-developing the drug with AstraZeneca PLC.

Anemia, a deficiency of red blood cells, common develops in association with the chronic kidney disease.